Dynamic Technology Lab Private Ltd Has $198,000 Position in BioTelemetry Inc. (BEAT)
Dynamic Technology Lab Private Ltd cut its stake in shares of BioTelemetry Inc. (NASDAQ:BEAT) by 51.2% during the second quarter, Holdings Channel reports. The fund owned 12,117 shares of the company’s stock after selling 12,723 shares during the period. Dynamic Technology Lab Private Ltd’s holdings in BioTelemetry were worth $198,000 as of its most recent filing with the SEC.
Several other hedge funds also recently made changes to their positions in the stock. Geode Capital Management LLC boosted its stake in shares of BioTelemetry by 2.1% in the first quarter. Geode Capital Management LLC now owns 177,680 shares of the company’s stock valued at $2,075,000 after buying an additional 3,654 shares during the last quarter. Springbok Capital Management LLC bought a new stake in shares of BioTelemetry during the first quarter valued at about $146,000. Acadian Asset Management LLC bought a new stake in shares of BioTelemetry during the second quarter valued at about $5,991,000. First Quadrant L P CA boosted its stake in shares of BioTelemetry by 56.4% in the second quarter. First Quadrant L P CA now owns 12,200 shares of the company’s stock valued at $199,000 after buying an additional 4,400 shares during the last quarter. Finally, Bank of Montreal Can bought a new stake in shares of BioTelemetry during the second quarter valued at about $164,000. Institutional investors and hedge funds own 78.28% of the company’s stock.
Shares of BioTelemetry Inc. (NASDAQ:BEAT) opened at 21.065 on Thursday. The firm has a 50-day moving average price of $19.01 and a 200-day moving average price of $16.56. The firm has a market capitalization of $590.35 million, a PE ratio of 44.819 and a beta of 0.73. BioTelemetry Inc. has a 1-year low of $8.74 and a 1-year high of $21.68.
BioTelemetry (NASDAQ:BEAT) last announced its quarterly earnings results on Tuesday, August 2nd. The company reported $0.20 earnings per share for the quarter, topping analysts’ consensus estimates of $0.17 by $0.03. BioTelemetry had a net margin of 7.11% and a return on equity of 25.36%. The firm earned $52.68 million during the quarter, compared to analysts’ expectations of $50.27 million. During the same period in the prior year, the company earned $0.12 EPS. The firm’s revenue was up 17.6% on a year-over-year basis. On average, analysts forecast that BioTelemetry Inc. will post $0.76 EPS for the current fiscal year.
BEAT has been the topic of several analyst reports. Zacks Investment Research cut BioTelemetry from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, July 26th. Benchmark Co. raised their price target on BioTelemetry from $20.00 to $25.00 and gave the company a “buy” rating in a research note on Wednesday, August 3rd. Sidoti assumed coverage on BioTelemetry in a research note on Tuesday, September 13th. They issued a “buy” rating and a $27.00 price target on the stock. Finally, Lake Street Capital restated a “buy” rating and issued a $24.00 price target on shares of BioTelemetry in a research note on Wednesday.
In other BioTelemetry news, SVP Daniel Wisniewski sold 9,025 shares of the business’s stock in a transaction on Friday, August 19th. The shares were sold at an average price of $20.96, for a total value of $189,164.00. Following the transaction, the senior vice president now owns 68,501 shares in the company, valued at approximately $1,435,780.96. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, SVP George Hrenko sold 4,149 shares of the business’s stock in a transaction on Monday, August 22nd. The stock was sold at an average price of $20.85, for a total transaction of $86,506.65. Following the completion of the transaction, the senior vice president now owns 103,888 shares in the company, valued at approximately $2,166,064.80. The disclosure for this sale can be found here. Corporate insiders own 11.00% of the company’s stock.
BioTelemetry, Inc (BioTelemetry), formerly CardioNet, Inc, provides cardiac monitoring services, cardiac monitoring device manufacturing, and centralized cardiac core laboratory services. The Company operates in three segments: patient services, product and research services. The patient services business segment’s principal focus is on the diagnosis and monitoring of cardiac arrhythmias or heart rhythm disorders, through its core Mobile Cardiac Outpatient Telemetry(MCOT), event and Holter services in a healthcare setting.
Want to see what other hedge funds are holding BEAT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for BioTelemetry Inc. (NASDAQ:BEAT).
Receive News & Ratings for BioTelemetry Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioTelemetry Inc. and related companies with MarketBeat.com's FREE daily email newsletter.